#separator:tab
#html:false
#notetype column:1
#tags column:4
Basic	SLE - Define systemic lupus erythematosus.	A generalized multisystem autoimmune disease of unknown cause characterized by production of autoantibodies (mainly ANAs) against nuclear antigens, immune complex deposition, and resulting inflammation/vasculitis causing multiorgan damage.	SLE
Basic	SLE - Typical age and sex distribution?	Women of reproductive age (15-40 yrs); F:M ratio ~4:1 after puberty (2:1 before puberty and after menopause). Higher incidence in African-American and Latino women.	SLE
Basic	SLE - Which HLA/MHC associations are seen?	HLA-DR2, DR3, DR4, and DR5.	SLE
Basic	SLE - Antibody found almost exclusively in SLE, targeting an RNA-protein complex?	Anti-Sm antibody.	SLE
Basic	SLE - Which antibody correlates best with lupus nephritis activity?	Anti-double-stranded DNA (anti-dsDNA) antibody.	SLE
Basic	SLE - Most sensitive screening antibody test?	Antinuclear antibody (ANA) - present in >95% of SLE patients but not specific.	SLE
Basic	SLE - Name the antibody associated with neonatal lupus and congenital heart block.	Anti-Ro (SS-A) antibody.	SLE
Basic	SLE - How many ACR classification criteria must be met for diagnosis?	At least 4 of 11 criteria, present serially or simultaneously.	SLE
Basic	SLE - What percentage of patients develop a mucocutaneous manifestation during the disease course?	More than 90%.	SLE
Basic	SLE - Describe the classic malar rash.	Butterfly-shaped erythematous rash over the malar area and nasal bridge, sparing the nasolabial folds; often precipitated by sun exposure; seen in about one-third of patients.	SLE
Basic	SLE - What is subacute cutaneous lupus erythematosus (SCLE)?	A photosensitive, non-scarring rash (annular or papulosquamous) on sun-exposed areas, strongly associated with anti-Ro antibodies.	SLE
Basic	SLE - Which renal biopsy classification system is used for lupus nephritis?	The ISN/RPS (International Society of Nephrology/Renal Pathology Society) classification, Class I-VI.	SLE
Basic	SLE - Which lupus nephritis class carries the worst prognosis and is treated most aggressively?	Class IV (diffuse proliferative glomerulonephritis).	SLE
Basic	SLE - What antiphospholipid antibodies should be tested for in SLE and why?	Lupus anticoagulant, anticardiolipin antibody, and anti-beta2-glycoprotein I; associated with thrombosis, recurrent miscarriage, and thrombocytopenia (antiphospholipid syndrome, seen in ~30-40% of SLE patients).	SLE
Basic	SLE - First-line drug for mild musculoskeletal and cutaneous SLE?	Hydroxychloroquine (also reduces flares and improves survival - used in almost all SLE patients).	SLE
Basic	SLE - Drug of choice for severe lupus nephritis induction therapy?	High-dose corticosteroids combined with mycophenolate mofetil or cyclophosphamide (IV pulse, e.g. Euro-Lupus/NIH regimen).	SLE
Basic	SLE - Name a biologic approved for SLE that targets B-cell survival.	Belimumab (anti-BLyS/BAFF monoclonal antibody). Anifrolumab (anti-type I interferon receptor) is also approved.	SLE
Basic	SLE - What causes drug-induced lupus and which antibody is characteristic?	Drugs such as hydralazine, procainamide, isoniazid; characterized by anti-histone antibodies (anti-dsDNA and anti-Sm usually negative).	SLE
Basic	SLE - 5-year survival rate after diagnosis?	Approximately 90%.	SLE
Basic	SLE - Why should SLE be differentiated from HIV serologically?	SLE frequently gives a false-positive HIV screening test.	SLE
Basic	Systemic Sclerosis - Define systemic sclerosis (scleroderma).	An immunologic disorder characterized by excessive fibrosis in multiple tissues, obliterative vascular disease, and autoimmunity (production of autoantibodies), with cutaneous involvement in ~95% but morbidity/mortality mainly from visceral (GI, lung, kidney, heart) involvement.	Systemic_Sclerosis
Basic	Systemic Sclerosis - Name the two clinical subtypes and their features.	1) Diffuse systemic sclerosis - widespread skin involvement, rapid progression, early visceral involvement. 2) Limited systemic sclerosis - skin involvement confined to fingers/face, late visceral involvement (CREST variant).	Systemic_Sclerosis
Basic	Systemic Sclerosis - Expand the CREST acronym.	Calcinosis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly, Telangiectasia.	Systemic_Sclerosis
Basic	Systemic Sclerosis - What are the three interrelated pathogenic processes?	Autoimmune responses, vascular damage (microvasculopathy), and excessive collagen deposition (fibrosis).	Systemic_Sclerosis
Basic	Systemic Sclerosis - Which T-helper subset and cytokines drive fibrosis?	CD4+ Th2 cells release IL-13; TGF-beta (from alternatively activated macrophages) stimulates fibroblast collagen and ECM synthesis.	Systemic_Sclerosis
Basic	Systemic Sclerosis - Antibody specific for diffuse systemic sclerosis?	Anti-DNA topoisomerase I (anti-Scl-70) antibody.	Systemic_Sclerosis
Basic	Systemic Sclerosis - Antibody specific for limited systemic sclerosis / CREST?	Anti-centromere antibody.	Systemic_Sclerosis
Basic	Systemic Sclerosis - Which antibody is associated with scleroderma renal crisis risk?	Anti-RNA polymerase III antibody.	Systemic_Sclerosis
Basic	Systemic Sclerosis - What GI complications are common?	Esophageal hypomotility/dysmotility (most common visceral manifestation), GERD, small bowel bacterial overgrowth, wide-mouth colonic diverticula.	Systemic_Sclerosis
Basic	Systemic Sclerosis - Which serious pulmonary complications occur?	Interstitial lung disease/pulmonary fibrosis and pulmonary arterial hypertension (a major cause of death).	Systemic_Sclerosis
Basic	Systemic Sclerosis - What is scleroderma renal crisis and how is it treated?	Acute onset of malignant hypertension and rapidly progressive renal failure; treated urgently with ACE inhibitors (e.g. captopril), which dramatically improved prognosis.	Systemic_Sclerosis
Basic	Systemic Sclerosis - First-line treatment of Raynaud phenomenon in systemic sclerosis?	Calcium channel blockers (e.g. nifedipine); avoid cold exposure and smoking. PDE5 inhibitors or endothelin receptor antagonists for severe/digital ulcers.	Systemic_Sclerosis
Basic	Systemic Sclerosis - What drug is used to slow skin/lung fibrosis progression in early diffuse disease?	Mycophenolate mofetil (or cyclophosphamide); nintedanib is approved for SSc-associated interstitial lung disease.	Systemic_Sclerosis
Basic	Systemic Sclerosis - What is the skin histological hallmark?	Dense dermal fibrosis with atrophy of epidermis and adnexal structures, hyalinization and thickening of dermal collagen, and progressive obliteration of small vessels.	Systemic_Sclerosis
Basic	Systemic Sclerosis - Why is systemic sclerosis considered a vascular disease as much as a fibrotic one?	Microvascular endothelial injury occurs early, with intimal proliferation and narrowing of vessels leading to ischemia (Raynaud phenomenon, digital ulcers, pulmonary hypertension, renal crisis) independent of fibrosis.	Systemic_Sclerosis
Basic	Sjogren Syndrome - Define Sjogren syndrome.	An autoimmune disorder, likely T-cell mediated, causing lymphocytic destruction of exocrine glands, producing keratoconjunctivitis sicca (dry eyes) and xerostomia (dry mouth).	Sjogren
Basic	Sjogren Syndrome - Differentiate primary vs secondary Sjogren syndrome.	Primary SS occurs alone; secondary SS occurs in association with another autoimmune disease such as RA, SLE, systemic sclerosis, polymyositis, or primary biliary cirrhosis.	Sjogren
Basic	Sjogren Syndrome - What test measures tear production objectively?	Schirmer test (< 8-10 mm wetting of filter paper in 5 minutes indicates decreased tear production).	Sjogren
Basic	Sjogren Syndrome - What stain demonstrates keratoconjunctivitis sicca on the cornea/conjunctiva?	Rose bengal staining (lissamine green is also used).	Sjogren
Basic	Sjogren Syndrome - What is the gold-standard test for definitive diagnosis?	Minor salivary gland (lip) biopsy showing focal lymphocytic sialadenitis (focus score >=1 per 4 mm2).	Sjogren
Basic	Sjogren Syndrome - Which autoantibodies are characteristic of Sjogren syndrome?	Anti-Ro (SS-A) and anti-La (SS-B) antibodies; also RF and ANA are frequently positive.	Sjogren
Basic	Sjogren Syndrome - List exclusion criteria (conditions that mimic SS) per the San Diego criteria.	HIV infection, sarcoidosis, pre-existing lymphoma, hepatitis B or C infection, primary fibromyalgia, and other causes of keratitis sicca or salivary gland enlargement.	Sjogren
Basic	Sjogren Syndrome - Major long-term malignant complication and its warning sign?	Non-Hodgkin (MALT/B-cell) lymphoma; suspect with persistent salivary gland enlargement, palpable purpura, or low complement/monoclonal gammopathy.	Sjogren
Basic	Sjogren Syndrome - What renal tubular disorder is associated with Sjogren syndrome?	Distal (type 1) renal tubular acidosis due to lymphocytic infiltration of the renal interstitium.	Sjogren
Basic	Sjogren Syndrome - Mainstay symptomatic treatment for dry eyes and dry mouth?	Artificial tears/lubricants for eyes; sugar-free gum, frequent sips of water, and muscarinic agonists (pilocarpine, cevimeline) to stimulate residual salivary/lacrimal secretion.	Sjogren
Basic	Sjogren Syndrome - Which systemic drug is used for severe extraglandular or systemic disease (e.g. vasculitis)?	Hydroxychloroquine for mild disease; rituximab or corticosteroids/immunosuppressants for severe systemic (extraglandular) manifestations.	Sjogren
Basic	Mixed Connective Tissue Disease - Define MCTD.	A distinct overlap syndrome combining clinical features of SLE, systemic sclerosis, and polymyositis, characterized serologically by very high-titer ANA (speckled pattern) with antibodies against U1-RNP (a ribonuclease-sensitive extractable nuclear antigen).	MCTD
Basic	Mixed Connective Tissue Disease - What is the defining serologic marker?	High-titer anti-U1-RNP antibody, typically in the absence of anti-Sm antibody.	MCTD
Basic	Mixed Connective Tissue Disease - Which HLA types are linked to MCTD?	HLA-DR4 and HLA-DR2.	MCTD
Basic	Mixed Connective Tissue Disease - Name the classic early, non-specific presenting symptoms.	Malaise, fatigue, myalgias, arthralgias, and low-grade fever.	MCTD
Basic	Mixed Connective Tissue Disease - Describe the characteristic hand finding.	"Sausage-like" diffusely swollen fingers/hands, often with Raynaud phenomenon.	MCTD
Basic	Mixed Connective Tissue Disease - How does MCTD differ from SLE in terms of severe organ involvement?	Patients with anti-U1RNP-positive MCTD infrequently develop major CNS disease or severe proliferative glomerulonephritis compared with SLE.	MCTD
Basic	Mixed Connective Tissue Disease - What proportion of MCTD patients develop renal involvement, and what is the typical presentation?	About 10-26% of adults (33-50% of children); usually mild with microhematuria and proteinuria <500 mg/day, though severe hypertension/AKI resembling scleroderma renal crisis can occur.	MCTD
Basic	Mixed Connective Tissue Disease - Distinguish MCTD from "overlap syndrome" and "undifferentiated connective tissue disease (UCTD)."	Overlap syndrome = patient fully meets diagnostic criteria for 2+ distinct CTDs simultaneously. UCTD = features of CTD present but insufficient to classify as any specific disease. MCTD is a specific entity defined by anti-U1RNP plus overlapping clinical features; only ~4% of UCTD progresses to MCTD.	MCTD
Basic	Mixed Connective Tissue Disease - What long-term outcome data exist on evolution of MCTD (8-year follow-up study)?	Of 161 patients: 60% remained unclassified MCTD, 17% evolved into systemic sclerosis, 9% into SLE, 2.5% into RA, 11.5% into undifferentiated CTD. Positive anti-dsDNA predicted evolution to SLE; esophageal hypomotility/sclerodactyly predicted evolution to systemic sclerosis.	MCTD
Basic	Mixed Connective Tissue Disease - Leading causes of death in MCTD?	Pulmonary arterial hypertension and pulmonary fibrosis, cardiovascular events, renal disease, CNS disease, thrombotic thrombocytopenic purpura, and infection.	MCTD
Basic	Mixed Connective Tissue Disease - First-line treatment for inflammatory arthritis/myositis flares in MCTD?	Corticosteroids (e.g. prednisone ~1 mg/kg/day); steroid-sparing immunosuppressants and bisphosphonates should be added early to limit steroid-related osteoporosis.	MCTD
Basic	Mixed Connective Tissue Disease - Which feature of MCTD responds best to treatment, and which responds worst?	Lupus-like (SLE) features respond best to therapy; scleroderma-like features respond least well.	MCTD
Basic	Mixed Connective Tissue Disease - Overall prognosis of MCTD compared with systemic sclerosis?	Generally better than systemic sclerosis, mainly due to a lower incidence of severe renal disease.	MCTD
Basic	Compare defining autoantibodies: SLE vs Systemic Sclerosis (diffuse) vs Systemic Sclerosis (limited/CREST) vs Sjogren vs MCTD.	SLE: anti-dsDNA, anti-Sm. Diffuse SSc: anti-Scl-70 (topoisomerase I). Limited SSc/CREST: anti-centromere. Sjogren: anti-Ro (SS-A), anti-La (SS-B). MCTD: anti-U1-RNP (high titer, anti-Sm negative).	Comparative
Basic	Compare which connective tissue disease is LEAST likely to cause severe nephritis or CNS disease despite a high ANA titer.	Mixed connective tissue disease (MCTD) - anti-U1RNP-positive patients rarely get severe proliferative glomerulonephritis or major CNS disease, unlike SLE.	Comparative
Basic	Which two connective tissue diseases share Raynaud phenomenon as a near-universal early feature?	Systemic sclerosis and mixed connective tissue disease (also common in SLE and Sjogren but less universal).	Comparative

#separator:tab
#html:false
#notetype column:1
#tags column:4
Basic	VIGNETTE (SLE): A 24-year-old woman presents with malar rash worsening after sun exposure, polyarthralgia, and facial puffiness. Urinalysis shows proteinuria and RBC casts. ANA is 1:640, anti-dsDNA is markedly elevated, and C3/C4 are low. What is the diagnosis and the single most important next investigation?	Systemic lupus erythematosus with suspected lupus nephritis. Next step: renal biopsy to determine the ISN/RPS class of lupus nephritis, which guides treatment intensity (e.g. Class III/IV needs aggressive induction with steroids + mycophenolate/cyclophosphamide).	SLE_Vignette
Basic	VIGNETTE (SLE): A 32-year-old woman on isoniazid for latent TB develops arthralgia, malar-sparing rash, and a positive ANA. Anti-histone antibody is positive; anti-dsDNA and anti-Sm are negative. What is the diagnosis and management?	Drug-induced lupus (isoniazid is a classic cause, along with hydralazine and procainamide). Management: discontinue the offending drug; symptoms usually resolve over weeks to months. Renal and CNS involvement are rare in drug-induced lupus.	SLE_Vignette
Basic	VIGNETTE (SLE): A pregnant woman with known SLE and positive anti-Ro (SS-A) and anti-La (SS-B) antibodies is found to have fetal bradycardia (heart rate 60/min) on routine obstetric ultrasound at 24 weeks. What is the diagnosis and what drug reduces recurrence risk in a future pregnancy?	Congenital complete heart block due to neonatal lupus (transplacental transfer of anti-Ro/La antibodies causing fibrosis of the fetal conducting system). Hydroxychloroquine given throughout pregnancy reduces the risk of recurrent congenital heart block in subsequent pregnancies.	SLE_Vignette
Basic	VIGNETTE (SLE): A woman with SLE has had two first-trimester miscarriages and one episode of unprovoked DVT. Labs show thrombocytopenia and a prolonged aPTT that does not correct with mixing studies. What is the underlying diagnosis and which antibody has the strongest association with these clinical events?	Secondary antiphospholipid syndrome (APS) complicating SLE. Lupus anticoagulant (LAC) has the strongest association with thrombosis and pregnancy morbidity among the antiphospholipid antibodies (compared to anticardiolipin or anti-beta2-glycoprotein I).	SLE_Vignette
Basic	VIGNETTE (SLE): A known SLE patient on chronic immunosuppression presents with fever, and labs show a rising anti-dsDNA titer with falling C3/C4. A second patient with similar fever has stable complement and antibody titers but an elevated procalcitonin. How do you differentiate a lupus flare from infection in these two patients?	Rising anti-dsDNA with falling complement (C3/C4) favors an active SLE flare (immune complex consumption of complement). Normal/stable serology with elevated procalcitonin and often elevated CRP disproportionate to ESR favors infection. Both can coexist, so clinical correlation and cultures are essential before escalating immunosuppression.	SLE_Vignette
Basic	VIGNETTE (SLE): An SLE patient on long-term hydroxychloroquine therapy comes for a routine follow-up. What monitoring is mandatory and why?	Annual (or baseline + annual after 5 years) ophthalmologic examination with visual fields/OCT, because hydroxychloroquine can cause irreversible bull's-eye maculopathy (retinopathy) with long-term use.	SLE_Vignette
Basic	VIGNETTE (SLE): A 26-year-old woman with SLE presents with acute confusion, new-onset seizure, and no focal neurological deficit. Infection workup and metabolic panel are unremarkable. MRI brain shows no acute infarct. What is the likely diagnosis and initial treatment approach?	Neuropsychiatric SLE (NPSLE). After excluding infection, metabolic causes, and stroke/thrombosis (check antiphospholipid antibodies), treatment is with high-dose corticosteroids plus immunosuppression (e.g. cyclophosphamide or mycophenolate) for severe NPSLE.	SLE_Vignette
Basic	VIGNETTE (SLE): A 29-year-old woman presents with fatigue and a rash on sun-exposed skin (upper chest and arms) that is annular and non-scarring. She denies significant joint or renal symptoms. Serology shows a strongly positive anti-Ro (SS-A) antibody. What specific cutaneous lupus subtype is this and what antibody is it linked to?	Subacute cutaneous lupus erythematosus (SCLE) - a photosensitive, non-scarring annular/papulosquamous rash strongly associated with anti-Ro (SS-A) antibodies.	SLE_Vignette
Basic	VIGNETTE (Systemic Sclerosis): A 45-year-old woman has a 4-month history of Raynaud phenomenon, puffy fingers, and now rapidly progressive skin tightening involving the face, trunk, and proximal limbs. Anti-Scl-70 (topoisomerase I) is positive. What is the diagnosis and expected disease course?	Diffuse cutaneous systemic sclerosis. Expect rapid skin progression with early visceral involvement (lung ILD, renal crisis risk, cardiac involvement) - this subtype has a more aggressive course than limited disease.	SSc_Vignette
Basic	VIGNETTE (Systemic Sclerosis): A 52-year-old woman has had Raynaud phenomenon for 15 years, with skin tightening limited to the fingers and face, subcutaneous calcinosis nodules, telangiectasia over the cheeks, and dysphagia to solids. Anti-centromere antibody is positive. What is the diagnosis and which acronym describes this constellation?	Limited cutaneous systemic sclerosis (CREST syndrome): Calcinosis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly, Telangiectasia.	SSc_Vignette
Basic	VIGNETTE (Systemic Sclerosis): A patient with early diffuse systemic sclerosis who was recently started on high-dose corticosteroids for myositis presents with a sudden severe headache, blood pressure 220/120 mmHg, and oliguria. Blood smear shows schistocytes. What is the diagnosis, the likely precipitating factor, and the immediate treatment?	Scleroderma renal crisis, precipitated by high-dose corticosteroid use (a recognized risk factor, along with early diffuse disease and anti-RNA polymerase III antibody). Immediate treatment: ACE inhibitors (e.g. captopril), titrated aggressively regardless of renal function, which have dramatically improved outcomes; up to two-thirds of patients may still need transient or permanent dialysis.	SSc_Vignette
Basic	VIGNETTE (Systemic Sclerosis): A systemic sclerosis patient reports progressive exertional dyspnea and dry cough. HRCT chest shows bibasilar ground-glass opacities and reticulation. What is the diagnosis and name two disease-modifying treatment options.	Systemic sclerosis-associated interstitial lung disease (SSc-ILD). Treatment options: mycophenolate mofetil or cyclophosphamide (immunosuppression), and nintedanib (an antifibrotic) is approved to slow progression of SSc-ILD.	SSc_Vignette
Basic	VIGNETTE (Systemic Sclerosis): A systemic sclerosis patient develops dyspnea on exertion with a loud P2 on auscultation. Spirometry is near normal, but DLCO is disproportionately reduced compared to FVC. What complication is suspected and what test confirms it?	Pulmonary arterial hypertension (PAH), a leading cause of SSc mortality. Screen with echocardiography (estimated RVSP); confirm with right heart catheterization (mean pulmonary artery pressure >20 mmHg with appropriate hemodynamic criteria).	SSc_Vignette
Basic	VIGNETTE (Systemic Sclerosis): A systemic sclerosis patient reports early satiety, bloating, and iron-deficiency anemia. Upper endoscopy reveals longitudinal red stripes radiating from the pylorus. What is this finding called and what is the treatment?	"Watermelon stomach" - gastric antral vascular ectasia (GAVE). Treatment: endoscopic argon plasma coagulation; iron supplementation for associated anemia.	SSc_Vignette
Basic	VIGNETTE (Systemic Sclerosis): A patient with systemic sclerosis has recurrent digital ulcers on the fingertips unresponsive to conservative measures (avoiding cold, stopping smoking). What pharmacologic options can be tried in a stepwise manner?	Calcium channel blockers (e.g. nifedipine) first-line for Raynaud phenomenon; if refractory, add PDE5 inhibitors (sildenafil) or endothelin receptor antagonists (bosentan) for severe Raynaud/digital ulcers; IV prostanoids (iloprost) for critical ischemia.	SSc_Vignette
Basic	VIGNETTE (Sjogren Syndrome): A 55-year-old woman reports dry eyes and dry mouth for 3 years, with difficulty swallowing dry foods. Schirmer test shows <8 mm wetting at 5 minutes bilaterally, and rose bengal staining shows corneal punctate keratopathy. Anti-Ro and anti-La are strongly positive. What is the diagnosis and what test would make it "definite" rather than "probable"?	Primary Sjogren syndrome (probable, based on objective dryness plus serology). A minor salivary gland (lip) biopsy showing focal lymphocytic sialadenitis (focus score >=1) is required to confirm "definite" Sjogren syndrome.	Sjogren_Vignette
Basic	VIGNETTE (Sjogren Syndrome): A patient with established rheumatoid arthritis develops new-onset dry eyes and dry mouth over several months. What is this presentation called and how does it differ diagnostically from primary Sjogren syndrome?	Secondary Sjogren syndrome (occurring in association with another defined autoimmune disease such as RA, SLE, or systemic sclerosis). Diagnostic workup for dryness (Schirmer test, salivary flow, anti-Ro/La) is the same, but the classification requires the coexisting connective tissue disease to be present.	Sjogren_Vignette
Basic	VIGNETTE (Sjogren Syndrome): A long-standing Sjogren syndrome patient develops unilateral firm parotid gland enlargement, unintentional weight loss, and new palpable cervical lymphadenopathy. What serious complication must be excluded and how?	Non-Hodgkin (MALT-type) B-cell lymphoma - a well-recognized long-term complication of Sjogren syndrome. Evaluate with salivary gland biopsy/imaging, and check for risk markers such as persistent parotid swelling, palpable purpura, low C4, cryoglobulinemia, or monoclonal gammopathy.	Sjogren_Vignette
Basic	VIGNETTE (Sjogren Syndrome): A Sjogren syndrome patient presents with generalized muscle weakness. Labs show hypokalemia and a urine pH of 6.5 despite systemic metabolic acidosis. What renal complication does this represent?	Distal (type 1) renal tubular acidosis, caused by lymphocytic infiltration of the renal interstitium in Sjogren syndrome - the inability to acidify urine despite systemic acidosis is the key clue.	Sjogren_Vignette
Basic	VIGNETTE (Sjogren Syndrome): A Sjogren syndrome patient is prescribed pilocarpine for severe xerostomia. Which comorbidities would make this drug relatively contraindicated?	Asthma/COPD (bronchospasm risk), narrow-angle glaucoma, and significant cardiac conduction disease/bradyarrhythmias - because pilocarpine is a muscarinic agonist with cholinergic side effects.	Sjogren_Vignette
Basic	VIGNETTE (Sjogren Syndrome): A pregnant woman with known primary Sjogren syndrome and positive anti-Ro/anti-La antibodies asks about fetal risk. What should she be counseled about, and which drug may reduce this risk?	Risk of neonatal lupus syndrome, including congenital complete heart block and/or transient cutaneous rash in the neonate, due to transplacental transfer of anti-Ro/La antibodies (same mechanism as in SLE). Hydroxychloroquine during pregnancy may reduce the risk of recurrent congenital heart block.	Sjogren_Vignette
Basic	VIGNETTE (MCTD): A 28-year-old woman presents with Raynaud phenomenon, diffusely swollen "sausage-like" fingers, polyarthralgia, proximal muscle weakness with elevated CK, and dysphagia from esophageal dysmotility. ANA is strongly positive in a speckled pattern; anti-U1RNP is markedly elevated, and anti-Sm is negative. What is the diagnosis?	Mixed connective tissue disease (MCTD) - defined by overlapping features of SLE, systemic sclerosis, and polymyositis together with high-titer anti-U1RNP antibody in the absence of anti-Sm.	MCTD_Vignette
Basic	VIGNETTE (MCTD): A patient with known MCTD develops progressive exertional dyspnea over several months. Echocardiography shows an elevated estimated right ventricular systolic pressure with preserved left ventricular function. What complication is this and why is it clinically important?	Pulmonary arterial hypertension - it is one of the leading causes of death in MCTD (along with pulmonary fibrosis), so it should be screened for periodically with echocardiography in MCTD patients.	MCTD_Vignette
Basic	VIGNETTE (MCTD): An MCTD patient's urinalysis shows microscopic hematuria and proteinuria of 400 mg/day, with normal renal function. How does the expected severity of renal disease in MCTD compare with SLE, and what does this patient's presentation suggest?	Renal involvement in MCTD (typically anti-U1RNP-antibody driven) is usually milder than in SLE and rarely progresses to severe proliferative glomerulonephritis. This patient's mild microhematuria/subnephrotic proteinuria is consistent with the milder renal pattern seen in MCTD, though monitoring is still warranted since severe crises can rarely occur.	MCTD_Vignette
Basic	VIGNETTE (MCTD): A patient diagnosed with MCTD eight years ago now presents with progressive sclerodactyly and esophageal hypomotility, with the original overlapping features becoming less prominent. What does this evolution suggest about her long-term disease trajectory?	Longitudinal MCTD cohort data show that a subset of patients evolve over time into a defined connective tissue disease; sclerodactyly and esophageal hypomotility are known predictors of evolution toward systemic sclerosis (while a positive anti-dsDNA predicts evolution toward SLE).	MCTD_Vignette
Basic	VIGNETTE (MCTD): An MCTD patient develops an acute flare of inflammatory polyarthritis and myositis. What is the first-line treatment, and what preventive measure should be co-prescribed given anticipated therapy duration?	Corticosteroids (e.g. prednisone ~1 mg/kg/day) for the acute inflammatory flare, with early addition of a steroid-sparing immunosuppressant. Because of osteoporosis risk with prolonged steroid use, bisphosphonate therapy should be considered early.	MCTD_Vignette
Basic	VIGNETTE (Comparative): Four patients present with Raynaud phenomenon: (1) high anti-dsDNA and anti-Sm with nephritis, (2) anti-Scl-70 with rapidly progressive skin thickening, (3) anti-centromere with long-standing CREST features, (4) high anti-U1RNP with sausage fingers and myositis but no major renal/CNS disease. Match each to the most likely diagnosis.	(1) SLE, (2) Diffuse systemic sclerosis, (3) Limited systemic sclerosis/CREST, (4) Mixed connective tissue disease (MCTD).	Comparative_Vignette
Basic	VIGNETTE (Comparative): A patient has features that fully satisfy classification criteria for both systemic sclerosis and SLE simultaneously (not just overlapping but each disease independently classifiable). How should this be labeled, and how does it differ from MCTD?	This is termed an "overlap syndrome" - the patient meets full diagnostic criteria for two (or more) distinct connective tissue diseases at once. MCTD differs because it is a specific overlap entity defined by high-titer anti-U1RNP antibody with a characteristic clinical picture, not simply the co-existence of two independently-classifiable diseases.	Comparative_Vignette
Basic	VIGNETTE (Comparative): A 33-year-old woman with a longstanding diagnosis of one of the connective tissue diseases (SLE, systemic sclerosis, Sjogren, or MCTD) is planning pregnancy and is anti-Ro/anti-La positive. Regardless of which underlying disease she has, what fetal risk applies and what drug reduces it?	Anti-Ro/La antibodies (seen in SLE, secondary/primary Sjogren, and occasionally other CTDs) confer risk of neonatal lupus syndrome, most seriously congenital complete heart block, via transplacental antibody transfer. Hydroxychloroquine throughout pregnancy reduces the recurrence risk of congenital heart block.	Comparative_Vignette